Manulife (Manufacturers Life Insurance)
AXDX

Manulife (Manufacturers Life Insurance)’s Accelerate Diagnostics AXDX Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,211
Closed -$17.4K – 3018
2022
Q1 		$17.4K Sell
1,211
-475
-28% -$13.5K ﹤0.01% 3065
2021
Q4 		$88 Buy
1,686
+476
+39% +$26.5K ﹤0.01% 3065
2021
Q3 		$71K Sell
1,210
-894
-42% -$58.3K ﹤0.01% 3118
2021
Q2 		$170K Buy
2,104
+44
+2% +$3.5K ﹤0.01% 3169
2021
Q1 		$171K Buy
2,060
+11
+0.5% +$1.12K ﹤0.01% 2945
2020
Q4 		$155K Buy
2,049
+132
+7% +$11.8K ﹤0.01% 2853
2020
Q3 		$204K Hold
1,917
– – ﹤0.01% 2554
2020
Q2 		$277K Buy
1,917
+58
+3% +$5.72K ﹤0.01% 2307
2020
Q1 		$155K Buy
1,859
+131
+8% +$18.4K ﹤0.01% 2434
2019
Q4 		$292K Sell
1,728
-54
-3% -$8.91K ﹤0.01% 2355
2019
Q3 		$337K Sell
1,782
-43
-2% -$8.31K ﹤0.01% 2252
2019
Q2 		$418K Buy
1,825
+762
+72% +$149K ﹤0.01% 2153
2019
Q1 		$223K Buy
+1,063
New +$199K ﹤0.01% 2377
2018
Q4 		– Sell
-1,065
Closed -$244K – 2526
2018
Q3 		$244K Sell
1,065
-1,011
-49% -$224K ﹤0.01% 2636
2018
Q2 		$463K Hold
2,076
– – ﹤0.01% 2454
2018
Q1 		$474K Sell
2,076
-13
-0.6% -$3.41K ﹤0.01% 2374
2017
Q4 		$548K Sell
2,089
-39
-2% -$9.14K ﹤0.01% 2260
2017
Q3 		$478K Buy
2,128
+15
+0.7% +$3.68K ﹤0.01% 2306
2017
Q2 		$578K Buy
2,113
+243
+13% +$65.9K ﹤0.01% 2182
2017
Q1 		$452K Buy
1,870
+232
+14% +$53K ﹤0.01% 2270
2016
Q4 		$340K Sell
1,638
-37
-2% -$8.79K ﹤0.01% 2388
2016
Q3 		$457K Sell
1,675
-24
-1% -$5.31K ﹤0.01% 2138
2016
Q2 		$244K Buy
1,699
+83
+5% +$11.1K ﹤0.01% 2563
2016
Q1 		$223K Buy
1,616
+102
+7% +$14.4K ﹤0.01% 2519
2015
Q4 		$325 Buy
1,514
+30
+2% +$5.48K ﹤0.01% 2313
2015
Q3 		$240 Buy
1,484
+24
+2% +$5.19K ﹤0.01% 2493
2015
Q2 		$377 Sell
1,460
-111
-7% -$26.5K ﹤0.01% 2321
2015
Q1 		$353 Buy
1,571
+40
+3% +$8.36K ﹤0.01% 2310
2014
Q4 		$293 Sell
1,531
-19
-1% -$4.07K ﹤0.01% 2366
2014
Q3 		$333 Buy
1,550
+32
+2% +$6.22K ﹤0.01% 2267
2014
Q2 		$395K Buy
1,518
+580
+62% +$127K ﹤0.01% 2201
2014
Q1 		$205 Sell
938
-35
-4% -$5.19K ﹤0.01% 2692
2013
Q4 		$118 Buy
973
+852
+704% +$114K ﹤0.01% 3002
2013
Q3 		$16 Buy
121
+96
+384% +$8.57K ﹤0.01% 3211
2013
Q2 		$2K Buy
+25
New +$1.86K ﹤0.01% 3395

Other funds holding AXDX

GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $182M AUM 33.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BAM
Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s AXDX Position: Q2 2022 in Review

Manulife (Manufacturers Life Insurance) sold out of Accelerate Diagnostics (AXDX) in Q2 2022, closing a stake of 1,211 shares — an estimated $17.4K sold.

Manulife (Manufacturers Life Insurance) first reported a position in AXDX in Q2 2013 and held it in 35 quarters. The position peaked at $578K in Q2 2017. 74 funds tracked by Wall St. Rank hold AXDX as of Q2 2022.

  • Manulife (Manufacturers Life Insurance) reported no remaining Accelerate Diagnostics position as of Q2 2022 after selling out during the quarter.
  • Manulife (Manufacturers Life Insurance) sold 1,211 Accelerate Diagnostics shares in Q2 2022, an estimated $17.4K.
  • Manulife (Manufacturers Life Insurance) first reported a position in Accelerate Diagnostics in Q2 2013 and held it in 35 quarters.
  • Manulife (Manufacturers Life Insurance)'s Accelerate Diagnostics position peaked at $578K in Q2 2017.
  • 74 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2022.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q2 2022, filed 15 Aug 2022.